New study maps multiple myeloma to personalize future treatments

NCT ID NCT07582354

Recruiting now Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study is collecting genetic and clinical information from 520 people with multiple myeloma to better understand why the disease progresses or comes back. Researchers will analyze tumor DNA and RNA to find patterns linked to treatment response. The goal is to create a detailed map of the disease that could guide more personalized care in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict how multiple myeloma will behave and choose more personalized treatments for each patient.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may take years to influence patient care and might not lead to immediate changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

IRCCS AOU Policlinico Sant'Orsola
RECRUITING

Bologna, Bo, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.